Although both LMP1 and LMP2 are expressed in most EBV-associated cancers, LMP1 is the main driver of tumor progression and tumor escape from immune surveillance, because LMP1 acts as the viral equivalent of CD40 [14]. This evidence concerns the gene CD40 and neoplasm.